43 results about "DU145" patented technology

The invention discloses an application of bixanthone compound FLBG-1108 or its pharmaceutical salts in the preparation of anti-cancer drugs. It is found in the invention through experiments that the bixanthone compound FLBG-1108 has an obvious inhibitory effect on the multiplication of human non-small cells lung cancer cells H520, A549, H549, 1299, a human breast cancer cell MCF7, human prostatic cancer cells PC3, LNcaP, and DU145 and human intestinal cancer cells SW480 and HT-2P. The multiplication of human lung cancer cells H520 can be inhibited selectively by the bixanthone compound FLBG-1108. The good time and the concentration dependence can be presented. The value of IC50 after 48 h action is 2.90 muM. The cytotoxicity is not expressed at this concentration on normal renal epidermal cells. Further, the bixanthone compound FLBG-1108 can effectively induce the apoptosis of lung cancer cells H520 and prevent the multiplication of cancer cells. Meanwhile, no toxicity will be presented. The bixanthone compound FLBG-1108 can specifically interdict the cell cycle of lung cancer cells H520 in S phase and can therefore inhibit the multiplication of cancer cells. Therefore, the bixanthone compound FLBG-1108 can be developed into a new candidate drug with an anti-cancer effect especially an anti-lung cancer effect.

The invention belongs to the field of pharmacy and relates to a benzoquinone compound and use thereof for preparing an anti-tumour drug, in particular to preparation of Arnebinone B and use thereof for resisting lung cancer, prostatic cancer and nasopharynx cancer. The benzoquinone compound provided by the invention is Arnebinone B, which is separated from arnebiae. In-vitro anti-tumour activity experimental results show that the median inhibitory concentration of Arnebinone B on lung carcinoma cell A549 is 4.86 mu g / ml, the median inhibitory concentration of Arnebinone B on prostate cancer cell DU145 is 5.16 mu g / ml, the median inhibitory concentration of Arnebinone B on nasopharyngeal carcinoma cell KB is 5.2 mu g / ml, and the median inhibitory concentration of Arnebinone B on KB drug-resistant strain KB-VIN is 4.98 mu g / ml. The result shows that Arnebinone B can be used for preparing the anti-tumour drug, in particular drugs for treating lung cancer, prostatic cancer and nasopharynx cancer.

The invention provides a lead compound using human FKBP51 protein as a target as well as a screening method and an application thereof, and belongs to the field of biochemical pharmacy technology. A FK1 domain of the FKBP51 protein is used as a receptor, a FK506 binding pocket of the receptor is selected, a Glide program is used for carrying out molecular docking, 150 small molecule compounds are obtained by virtual screening from more than 1.50 million compounds, and fluorescence quenching experiments are carried out for checking binding effects between the compounds and FK1; binding characteristics between the target protein and the compounds with high docking effects are researched, activities of the screened small molecule compounds against prostate cancer cells are checked by using two kinds of selected cells including LNCaP and DU145, and at the same time structural biology researches are carried out for compounds formed by FKBP51 and the small molecule lead compounds. The invention also establishes a cell model and a mice model of CRPC, effectiveness of the lead compounds on CRPC are evaluated, mechanisms and rules of action between the lead compounds and the target protein on molecular level are illustrated, and a foundation is provided for research and development of new drugs for treating common prostate cancer and CRPC.

The invention belongs to the field of a traditional Chinese medicinal preparation, and in particular provides a preparation method of a Shenmei stomach-nourishing particle (containing ginseng and dark plum). The stomach-nourishing particle is prepared from the following medicinal raw materials: 140g of radix glehniae, 105g of safflower, 175g of dandelion, 175g of radices paeoniae alba, 117g of hawthorn, 105g of curcuma zedoary, 140g of radix salviae miltiorrhizae, 117g of radix angelicae sinensis, 35g of dark plum, 70g of elecampane inla root and 70g of liquorice root by virtue of macroporous resin, cation exchange resin and anion exchange resin, so that content is greatly improved and dosage is reduced. The invention also provides application of the Shenmei stomach-nourishing particle in preparing medicines for inhibiting proliferation of human prostatic cancer cells DU145.

The invention discloses a newly discovered pathway-GFPT1 regulating AMPK phosphorylation pathway that can affect the proliferation of prostate cancer. Specifically, shRNA interference technology was used to interfere with GFPT1 in DU145 cells to activate the activity of AMPK and inhibit cell proliferation. Crystal violet staining and Western blotting experiments confirmed that the inhibition of GFPT1 can activate the AMPK pathway and inhibit cell proliferation, thereby achieving The purpose of effective treatment of prostate cancer.

The invention discloses a traditional Chinese medicine composition used for treating prostatic cancer. The traditional Chinese medicine composition used for treating prostatic cancer comprises, by weight, 9 to 30 parts of Radix Astragali, 6 to 15 parts of gen-seng, 6 to 15 parts of Chinese wolfberry, 6 to 15 parts of epimeddium, 3 to 10 parts of rhizoma curcumae longae, 9 to 20 parts of radix salviae miltiorrhizae, 9 to 20 parts of Rhizoma Paridis, 3 to 10 parts of scorpion, and 6 to 15 parts of mythic fungus. The traditional Chinese medicine composition is suitable for patients with treating prostatic cancer caused by deficient root with overdo superficial, possesses inhibition effects on propagation and promotion effect on apoptosis of castration-resistant prostate cancer cell PC3 and DU145. The invention also discloses a drug of the traditional Chinese medicine composition used for treating prostatic cancer, and a preparation method of the drug.